Mycophenolate
Mycophenolate is an immunosuppressant medicine used to prevent organ rejection following kidney, heart, or liver transplantation and to treat certain autoimmune conditions, depending on the formulation and clinical indication. It works by inhibiting inosine monophosphate dehydrogenase (IMPDH), reducing the production of guanosine nucleotides required for T- and B-lymphocyte proliferation. Mycophenolate is available as oral tablets, capsules, and suspension, as well as intravenous formulations in selected settings. Common side effects include diarrhoea, nausea, vomiting, abdominal discomfort, and reduced blood cell counts. Serious risks include severe infections, bone marrow suppression, certain malignancies, and significant fetal harm, including miscarriage and birth defects. Treatment requires specialist supervision, with regular monitoring of blood counts, liver and kidney function, infection symptoms, and strict pregnancy-prevention precautions where applicable.
Mycophenolate was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Mycophenolate, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Mycophenolate from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Mycophenolate, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
